StemCell Therapy

ORLANDO, Fla.--(BUSINESS WIRE)--Amnion of Florida, a leading provider of alternative medicine utilizing cryopreserved placental cell allograft for advanced bioactive facial rejuvenation, is pleased to announce a partnership to enhance patient outcomes for joint pain and anti-aging therapies.

Amnion announces a partnership with Care First Medical Group, Inc. to improve patients experience with managed medical care and provide non-pharmaceutical solutions for joint repair/pain management and anti-aging. The goals of the collaboration are to provide alternatives to medical care and to help patients seeking to eliminate chronic joint pain, look younger, and take a more active role in mapping their medical care to avoid illness in the future.

Sabriya Rogers, President of Care First, states, Our Board-Certified primary care providers specialize in managed health, thus patients can take a proactive approach in deciding the course of their care, which yields a lower cost to patients, while keeping families together, and maintaining a high degree of medical care.

The partnership will provide more location options for patients. With offices throughout greater Orlando, Sanford, Leesburg, Palm Coast, and Longwood, patients will find a location nearby that fits busy schedules.

Our team of medical professionals and aestheticians at Amnion are excited to partner with Care First to provide enhanced medical care and rejuvenation services at our partnership locations, said Eusebio Coterillo, President of Amnion.

In a constantly changing field, Amnion of Florida, under the guidance of an on-site medical staff, provides the highest level of quality products and procedures in regenerative medicine. They offer cutting edge treatments that are shown to be effective, use FDA cleared or registered products, and are widely published and peer endorsed. The collaboration with Care First will bring added benefits such as managed care, urgent care, and programmed care for long term issues such as high blood pressure, diabetes, high cholesterol, asthma, and allergies in a full-service clinical setting.

More about Amnion of Florida

Amnion of Florida, based in Central Florida, is a leading provider of alternative medicine using cryopreserved placental cell transplants or allografts, processed from donated cellular birth tissue, which are natural alternatives to autologous regenerative medicine products. The primary function of our allogeneic regenerative treatments is to promote soft tissue joint/skin repair and regeneration mediated by growth factors and cells naturally found in placental tissue. These treatments have shown safety and efficacy in treating a variety of ailments including osteoarthritis, chronic ulcerative wounds, joint pain, skin rejuvenation, hair restoration, urinary incontinence, and ED. Learn more at http://www.amnion.us.

More about Care First Medical Group, Inc.

Care First, based in Central Florida, is focused on providing affordable healthcare for primary and urgent care needs through prevention, patient education, with the personal touch to improve communication with the patient, and patients overall health. Our vision is to transform the health care experience through a culture of caring, quality, safety, service, innovation, and excellence. Our goal is to be recognized by employees, physicians, patients and families, volunteers, and the community as a company that delivers results through our proactive approach to medicine. Learn more or schedule an appointment at (407) 449-0632.

Read this article:
Amnion of Florida Announces Greater Geographic Reach for Their Regenerative Health Services by Partnering With Care First Medical Group - Business...

For its promising investigational therapeutic approach to neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), BrainStorm Cell Therapeutics is theBuzz of BIO 2020 winnerin the Public Therapeutic Biotech category.

The Buzz of BIO contest identifies U.S. companies with groundbreaking, early-stage potential to improve lives. The event also is anopportunity to make investor connections that could take products to the next phase.

Ten biotechnology companies are nominated in each of the three categories ofBuzz of BIO: Public Therapeutic Biotech, Private Therapeutic Biotech, and Diagnostics and Beyond. In the Public Therapeutic Biotech category that BrainStorm won, nominated companies must be actively developing a publicly traded human treatment intended for review by theU.S. Food and Drug Administration (FDA).

As a developer of autologous cellular therapies treatments that use a patients own cells and tissues for debilitating neurodegenerative diseases, BrainStorm is now testing its NurOwn therapy for safety and effectiveness. The treatment involves extracting, from human bone, marrow-derived mesenchymal stem cells (MSCs), which are capable of differentiating into other cell types. The MSCs are then matured into a specific cell type that produces neurotrophic factors compounds that promote nervous tissue growth and survival. They are then reintroduced to the body via injection into muscles and/or the spinal canal.

Backed by a California Institute for Regenerative Medicine grant, Brainstorm has fully enrolledits randomized, double-blind, placebo-controlled Phase 3 clinical trial (NCT03280056) at six U.S. sites in California, Massachusetts, and Minnesota. Some 200 ALS patients are participating. A secondary safety analysis by the trials independent Data Safety Monitoring Board (DSMB) revealed no new concerns. Every two months, study subjects will be given three injections into the spinal canal of either NurOwn or placebo.

The trial is expected to conclude late this year. Results will be announced shortly afterward.

In a Phase 2 study (NCT02017912), which included individuals with rapidly progressing ALS, NurOwn demonstrated a positive safety profile as well as prospective efficacy.

The use of autologous MSC cells to potentially treat ALS was given orphan drug status by both the FDA and the European Medicines Agency.

Thanks to everyone who voted for BrainStorm during the Buzz of BIO competition,Chaim Lebovits, BrainStorm president and CEO, said in a press release. The entire management team at BrainStorm was very pleased with the results of this competition, and we look forward to presenting to an audience of accredited investors who may benefit from the companys story. We thank the BIO[Biotechnology Innovation Organization] team for singling out BrainStorms NurOwn as a key technology with the potential to improve lives.

As a contest winner, BrainStorm is invited to givea presentation at theBio CEO & Investor Conference, to be held Feb. 1011 in New York City, along with exposure to multiple industry elites and potential investors.

NurOwn cells also are being tested in a Phase 2 clinical study (NCT03799718) in patients with progressive multiple sclerosis.

Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours dElegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled Belle of the Concours.

Total Posts: 6

Ins holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Cincias e Tecnologias and Instituto Gulbenkian de Cincia. Ins currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.

Link:
BrainStorm Cell Therapeutics Wins 2020 'Buzz of BIO' Award for ALS Investigational Therapy - ALS News Today

XconomyNational

Cell and gene therapies are becoming more mainstream, but an essential aspect of the drug development process is talking with clinicians about how it would fit into their practice, according to Joe Dupere, CEO of UK-based regenerative medicine company Rexgenero.

Rexgenero is advancing an experimental cell therapy for critical limb ischemia, a chronic condition that causes severe burning pain in the feet or toes as a result of blocked arteries in the lower limbs. Patients often get ulcers that can lead to amputation of the affected limb.

The company, headquartered in London, has R&D and manufacturing operations in Spain. Dupere talked with journalist Mike Ward at BIO-Europe 2019 in Hamburg, Germany, about the companys progress and plans.

Theres a lot of dialogue with the physicians and the surgeons that we cooperate with in our trial so they understand our product, its place in the treatment of this disease, and understanding when they can bring in patients and potential benefits, Dupere said.

When it comes to involving clinicians in its studies, the earlier, the better, Dupere said he learned as the company advanced its investigational treatments.

We live and breathe our design of our study, but surgeons are coming into this new, and to really understand how it works and really assist them in that journey with us so that they can bring patients in, we make it as easy as possible for them to participate, he said.

Although the type of treatment isnt as unusual as it once was, detailing how Rexgeneros cell therapies could impact how care is currently provided is essential to getting buy-in from the physicians who would use it, he said.

The challenge for us is to really demonstrate the superiority, in terms of the efficacy that we can show, and how that fits in with their practice, he said. Thats also marrying what they do already, which is a series of surgical and in endovascular procedures, [with] where the cell therapies can come in and really turbocharge that and have a really substantial impact on their patients.

As Rexgenero focuses on its Phase 3 trials, its priorities have included thinking through how the product would be used if it were to make it to commercialization.

Theres a whole range of other activities that we need to focus on as we get nearer to the market, he said.One is scaling up the manufacture, so thats a truly commercial manufacturing process that can really deliver the product to as many patients as possible. The second is really understanding how this would be used in practice, so from a commercial perspective, how would you sell this product, how would you position it with the physicians, and how would you get the surgeons to understand where this treatment would work in their general practice.

Duprere said the company also aims to expand into supplementary indications and establish a presence in the US.

Talking with investors as BIO-Europe, Duprere said he noticed more of an appreciation for biotechs that are doing cell therapy work outside of immune-oncology, a hot area for life sciences financings.

I think when you talk about [strategic investors], the core value proposition of the disease and the treatment of the disease and the unmet need of the disease has been understood from the beginning, but utilization of a cell therapy to be able to address that market is something that theyre getting much more familiar with, certainly around things like the manufacture, some of the regulation thats specific to cell therapies, and also the commercial path, when youre dealing with a curative product where you give a single dose of the product and you expect a cure for the patient.

Sarah de Crescenzo is an Xconomy editor based in San Diego. You can reach her at sdecrescenzo@xconomy.com.

View original post here:
Rexgenero CEO Talks Importance of Dialogue in Cell Therapy Conversations - Xconomy

MEDIA CONTACT

Available for logged-in reporters only

9th Annual Glaucoma 360, February 6 to 8, 2020, San Francisco

Newswise San Francisco, CA January 2, 2020: Glaucoma Research Foundation (GRF) will host the 9th Annual Glaucoma 360 from February 6 to 8, 2020 in San Francisco. This signature three-day event highlights innovation in glaucoma therapies to ensure patients have access to the latest and most effective diagnostic tools and treatment options. All Glaucoma 360 events will take place at the Grand Hyatt San Francisco in Union Square.

Glaucoma 360 begins on Thursday evening (February 6th) with a fundraising Gala. At the Gala, the 2020 Catalyst Award will be presented toVicente Anido, Jr, PhD and Thomas A. Mitro from Aerie Pharmaceuticals, Inc., in recognition of their remarkable leadership and commitment to the development of innovative glaucoma treatments.

During the Gala, Glaucoma Research Foundation will also be recognizing extraordinary research with the following presentations:

The New Horizons Forum on February 7th will feature more than 60 speakers from companies developing innovative glaucoma therapies and diagnostics. This full-day meeting co-founded and co-chaired byAdrienne L. Graves, PhDandAndrew G. Iwach, MD, spotlights new and promising developments to diagnose and treat glaucoma, a leading cause of preventable blindness worldwide. Since its inception in 2012, this meeting has grown substantially, attracting key clinical, scientific, industry, financial, and regulatory leaders from across the United States and around the world.

We will once again feature early-stage companies and their new technologies and approaches to glaucoma care, said Dr. Graves. The amount of innovation that is flourishing in the glaucoma space right now is phenomenal. As a result, there are more therapeutic options than ever before to help patients. Glaucoma 360 is an important catalyst to bring all the important elements together that can advance a promising idea into clinical use, she said.

Dr. Iwach added, For our 2020 New Horizons Forum, in addition to highlighting new developments in glaucoma diagnostics and therapies, there will also be a session on Innovation 101 that will discuss how you move from a great idea into the next breakthrough therapy for patients. The FDA will be involved in this session as their guidance is critical to get new and more effective solutions to our patients.

David W. Parke II, MD, Chief Executive Officer of the American Academy of Ophthalmology (AAO), will deliver the Drs. Henry and Frederick Sutro Memorial Lecture, the Forums keynote address. Dr. Parkes lecture, When Cost and Innovation Collide in Ophthalmology, will highlight the Academys role in facilitating innovation through collaboration with industry partners, AAO members, and AAO resources such as the IRIS registry the nation's first comprehensive eye disease clinical registry.

Glaucoma 360 will conclude on Saturday, February 8th with continuing medical education symposia for ophthalmologists and optometrists. The Shaffer-Hetherington-Hoskins Keynote Lecture on Saturday morning will be presented byDale K. Heuer, MD, Retired Professor and Chair of Ophthalmology and Visual Sciences, Medical College of Wisconsin in Milwaukee. More than 1,000 attendees are expected to participate over the three days of Glaucoma 360. All proceeds from the events support Glaucoma Research Foundations research and educational programs. To learn more about Glaucoma 360 events and to register, visit:www.glaucoma360.org.

About Glaucoma Research Foundation

Founded in San Francisco in 1978, Glaucoma Research Foundation is Americas oldest and most experienced institution dedicated to its mission to cure glaucoma and restore vision through innovative research. The Foundation has a proven track record of pioneering, results-oriented research and produces definitive educational materials used by eye care professionals across the country. The Glaucoma Research Foundation website,www.glaucoma.org, provides valuable information about glaucoma to 4 million visitors annually.

For more information about Glaucoma Research Foundation and Glaucoma 360 events, please contact, Brizette Castellanos at 415.986.3162, ext. 221, or brizette@glaucoma.org or visitwww.glaucoma360.org.

Continue reading here:
Glaucoma Research Foundation to Host 9th Annual Glaucoma 360 at Grand Hyatt in San Francisco - Newswise

At the 200-year mark, some institutions would be content to rest on their laurels. But not Indiana University. As their bicentennial celebrations nears, the Hoosiers have dedicated themselves to a tackling what they are calling Grand Challenges, a suite of economic, social and environmental problems plaguing Indiana and the world. These challenges are marked by their impressive scale, immense impact, driven commitment to solutions, and a spirit of interdisciplinary collaboration.

One of the Grand Challenges is the Precision Health Initiative, which aims to match patients more closely and carefully with treatments that meet their individual needs. According to Anatha Shekhar, the executive associate dean of research affairs at the Indiana University School of Medicine, the initiative derives that precision by taking a decidedly holistic look at a patient's health.

"What we're trying to do here is to have a comprehensive approach to understanding a person's health, taking into account their genetics, their environment, their behavior, their culture, and to understand the diseases that are caused by these factors," Shekar explains. "We're particularly focusing on five major serious illnesses that currently have no good treatments and that are uniformly lethal or disabling."

Those five diseases include three types of cancer: triple-negative breast cancer, multiple myeloma, and pediatric sarcoma. They're also targeting diabetes, in particular gestational diabetes affecting pregnant women, as well as Alzheimer's disease.

The Precision Health Initiative was the first project to receive Grand Challenges funding. A truly transformative undertaking, Indiana is pulling together researchers and physicians from across the university ecosystem to create new approaches to prevention, treatment and health care delivery.

"The Precision Health Initiative is trying to just marshal the great resources we have here, all the scientific minds, all the technology, to attack big, bold problems," says Aaron Carroll, professor of pediatrics and associate dean for research mentoring at the IU School of Medicine.

The project is funneling $120 million into six different major scientific pillars: Genomic Medicine; Cell, Gene & Immune Therapy; Regenerative Medicine & Engineering; Psychosocial, Behavioral & Ethics; Data & Informatics; and Chemical Biology & Biotherapeutics.

Carroll likens it all to a moonshot. Where research is normally understood to move slowly, taking tiny steps towards a solution, Indiana seeks great strides founded in unfettered access to both real and mental capital. And, as the only medical school in the state, as well as a regional and national research leader, their charge is an imperative. "It's certainly very Hoosier. I think the idea that we're going to take our local expertise and really try to band together and cross boundaries to try to make a big difference, it's, it's very Indiana," Carroll says.

Clinically speaking, the Precision Health Initiative is not just seeking to draw down instances of the maladies their targeting. Rather, they seek wholesale cures for the cancers, and robust, workable preventative measures for diabetes and Alzheimer's disease.

Their patient-focused approach is already being taught to physicians-in-training at the IU School of Medicine. The importance of factors such as genetic and family medical history, sleep and eating habits, exercise levels and overall mental health is emphasized alongside traditional testing in making a diagnosis.

In the lab, Indiana researchers are matching that holistic approach to patient health with an equally vibrant understanding of how diseases operate. They're working towards a more-perfect model of exactly how cancers evolve and how they become resistant to certain treatments. Concurrently, pharmaceutical scientists are making gains in drug discovery for the treatment of Alzheimer's.

Shekhar says that the feeling among the Precision Health Initiative team is that the work being done now is serving as inspiration for others to "think big and to go for the fences rather than do incremental work."

There are, though, factors limiting the speed at which the team can make new discoveries. Key among them is the need for an expansion in data analysis and management as well as advances need in AI to help researchers make sense of extremely large data sets.

One such set derives from the All In project, which is under the Precision Health Initiative umbrella. Researchers are asking people from across the state and all walks of life to share with them a blood sample as well as specific, yet anonymous health data. This will aid immensely in their understanding of how and why diseases flourish and progress in various populations.

That particular project is indicative of the larger initiative, says Shekhar, echoing Carroll's sentiment that Indiana is uniquely positioned to helm such an audacious undertaking.

"I think Indiana is unique in that first of all, we have the largest medical school in the country, that is a state wide medical school with nine campuses," he says. "We have the largest health system in the state. We serve about two million people every year for their health needs. So, we have gone all the way from engaging large scientific teams, recruiting nearly 50 new scientists to Indiana University to work on this, to engaging nearly hundred thousand people from the community. It's an initiative that couldn't happen in very many places except in Indiana."

See the rest here:
Inside Indiana's Precision Health Initiative: BTN LiveBIG - Big Ten Network

Cell and Advanced Therapies Supply Chain Management Market: Focus on Technological Solutions, 2019-2030report features an extensive study of the growing supply chain management software solutions market.

The focus of this study is on software systems, including cell orchestration platforms (COP), enterprise manufacturing systems (EMS), inventory management systems (IMS), laboratory information management systems (LIMS), logistics management systems (LMS), patient management systems (PMS), quality management systems (QMS), tracking and tracing software (TTS), and other such platforms that are being used to improve / optimize various supply chain-related processes of cell and advanced therapies.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the supply chain management software solutions market. Based on multiple parameters, such as number of cell and advanced therapies under development, expected pricing, likely adoption rates, and potential cost saving opportunities from different software systems, we have developed informed estimates of the evolution of the market, over the period 2019-2030.

In addition, we have provided the likely distribution of the current and forecasted opportunity across:

Advanced therapy medicinal products, such as cell and gene therapies, have revolutionized healthcare practices. The introduction of such treatment options has led to a paradigm shift in drug development, production and consumption. Moreover, such therapies have actually enabled healthcare providers to treat several difficult-to-treat clinical conditions.

In the past two decades, more than 30 such therapy products have been approved; recent approvals include Zolgensma (2019), RECELL System (2018), AmnioFix (2018), EpiFix (2018), EpiBurn (2018), Alofisel (2018), LUXTURNA (2017), Yescarta (2017), and Kymriah (2017). Further, according to a report published by The Alliance for Regenerative Medicine in 2019, more than 1,000 clinical trials are being conducted across the globe by over 900 companies.

In 2018, around USD 13 billion was invested in this domain, representing a 73% increase in capital investments in this domain, compared to the previous year. It is worth highlighting that, based on an assessment of the current pipeline of cell therapies and the historical clinical success of such products, it is likely that around 10-20 advanced therapies are approved by the US FDA each year, till 2025.

The commercial success of cell and advanced therapies is not only tied to whether they are capable of offering the desired therapeutic benefits, but also on whether the developers are able to effectively address all supply chain requirements. The advanced therapy medicinal products supply chain is relatively more complex compared to the conventional pharmaceutical supply chain. As a result, there are a number of risks, such as possible operational inefficiencies, capacity scheduling concerns, process delays leading to capital losses, and deliverable tracking-related issues, which need to be taken into consideration by therapy developers.

This has generated a need for bespoke technological solutions, which can be integrated into existing processes to enable the engaged stakeholders to oversee and manage the various aspects of the cell and advanced therapies supply chain, in compliance to global regulatory standards. Over the years, several innovative, software-enabled systems, offering supply chain orchestration and needle-to-needle traceability, have been developed.

The market has also recently witnessed the establishment of numerous partnerships, most of which are agreements between therapy developers and software solutions providers. Further, given the growing demand for cost-effective personalized medicinal products, and a myriad of other benefits of implementing such software solutions, the niche market is poised to grow significantly in the foreseen future.

Amongst other elements, the report features:

In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios portraying the conservative, base and optimistic tracks of the industry's evolution.

Continue reading here:
Supply Chain Management Software Solutions Market Will Grow Significantly in Coming Years - Supply and Demand Chain Executive

Dublin, Jan. 03, 2020 (GLOBE NEWSWIRE) -- The "Cell and Advanced Therapies Supply Chain Management Market, 2019-2030: Focus on Technological Solutions" report has been added to ResearchAndMarkets.com's offering.

Cell and Advanced Therapies Supply Chain Management Market: Focus on Technological Solutions, 2019-2030 report features an extensive study of the growing supply chain management software solutions market.

The focus of this study is on software systems, including cell orchestration platforms (COP), enterprise manufacturing systems (EMS), inventory management systems (IMS), laboratory information management systems (LIMS), logistics management systems (LMS), patient management systems (PMS), quality management systems (QMS), tracking and tracing software (TTS), and other such platforms that are being used to improve / optimize various supply chain-related processes of cell and advanced therapies.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the supply chain management software solutions market. Based on multiple parameters, such as number of cell and advanced therapies under development, expected pricing, likely adoption rates, and potential cost saving opportunities from different software systems, we have developed informed estimates of the evolution of the market, over the period 2019-2030.

In addition, we have provided the likely distribution of the current and forecasted opportunity across:

Advanced therapy medicinal products, such as cell and gene therapies, have revolutionized healthcare practices. The introduction of such treatment options has led to a paradigm shift in drug development, production and consumption. Moreover, such therapies have actually enabled healthcare providers to treat several difficult-to-treat clinical conditions.

In the past two decades, more than 30 such therapy products have been approved; recent approvals include Zolgensma (2019), RECELL System (2018), AmnioFix (2018), EpiFix (2018), EpiBurn (2018), Alofisel (2018), LUXTURNA (2017), Yescarta (2017), and Kymriah (2017). Further, according to a report published by The Alliance for Regenerative Medicine in 2019, more than 1,000 clinical trials are being conducted across the globe by over 900 companies.

In 2018, around USD 13 billion was invested in this domain, representing a 73% increase in capital investments in this domain, compared to the previous year. It is worth highlighting that, based on an assessment of the current pipeline of cell therapies and the historical clinical success of such products, it is likely that around 10-20 advanced therapies are approved by the US FDA each year, till 2025.

The commercial success of cell and advanced therapies is not only tied to whether they are capable of offering the desired therapeutic benefits, but also on whether the developers are able to effectively address all supply chain requirements. The advanced therapy medicinal products supply chain is relatively more complex compared to the conventional pharmaceutical supply chain. As a result, there are a number of risks, such as possible operational inefficiencies, capacity scheduling concerns, process delays leading to capital losses, and deliverable tracking-related issues, which need to be taken into consideration by therapy developers.

This has generated a need for bespoke technological solutions, which can be integrated into existing processes to enable the engaged stakeholders to oversee and manage the various aspects of the cell and advanced therapies supply chain, in compliance to global regulatory standards. Over the years, several innovative, software-enabled systems, offering supply chain orchestration and needle-to-needle traceability, have been developed.

The market has also recently witnessed the establishment of numerous partnerships, most of which are agreements between therapy developers and software solutions providers. Further, given the growing demand for cost-effective personalized medicinal products, and a myriad of other benefits of implementing such software solutions, the niche market is poised to grow significantly in the foreseen future.

Amongst other elements, the report features:

In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios portraying the conservative, base and optimistic tracks of the industry's evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

Key Topics Covered

1. PREFACE1.1. Scope of the Report1.2. Research Methodology1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION3.1. Context and Background3.2. An Introduction to Cell and Advanced Therapies3.2.1. Classification of Advanced Therapy Medicinal Products3.2.2. Current Market Landscape3.3. Cell and Advanced Therapies Supply Chain3.3.1. Key Processes3.3.2. Challenges Associated with the Cell and Advanced Therapies Supply Chain3.4. Software Solutions for Cell and Advanced Therapies Supply Chain Management3.4.1. Cell Orchestration Platform3.4.2. Enterprise Manufacturing System3.4.3. Inventory Management System3.4.4. Laboratory Information Management System3.4.5. Logistics Management System3.4.6. Patient Management System3.4.7. Quality Management System3.4.8. Tracking and Tracing System3.5. Growth Drivers and Roadblocks3.6. Emergence of Digital Technologies in Supply Chain Management3.6.1. Blockchain Technology3.6.2. Internet of Things3.6.3. Augmented Reality3.6.4. Big Data Analytics3.6.5. Artificial Intelligence

4. CURRENT MARKET LANDSCAPE4.1. Chapter Overview4.2. Cell and Advanced Therapies Supply Chain Management: Overall Market Landscape4.2.1. Analysis by Type of Software Solution4.2.2. Analysis by Key Specification and Benefit4.3.3. Analysis by Application4.3.4. Analysis by End User4.3.5. Analysis by Mode of Deployment4.3.6. Analysis by Scale of Management4.3.7. Analysis by Regulatory Certifications / Accreditations4.3. Cell and Advanced Therapies Supply Chain Management: Developer Landscape4.2.1. Analysis by Year of Establishment4.2.2. Analysis by Location of Headquarters4.2.3. Analysis by Size of Company4.3.4. Analysis by Support Services Offered4.3.5. Leading Developers: Analysis by Number of Software Solutions

5. COMPANY COMPETITIVENESS ANALYSIS5.1. Chapter Overview5.2. Methodology5.3. Assumptions and Key Parameters5.4. Competitiveness Analysis: Overview of Supply Chain Management Software Solution Providers5.4.1. Small-sized Companies5.4.2. Mid-sized Companies5.4.3. Large Companies

6. CORE SUPPLY CHAIN MANAGEMENT SOFTWARE SOLUTIONS: COMPANY PROFILES6.1. Chapter Overview6.2. Brooks Life Sciences6.2.1. Company Overview6.2.2. Financial Information6.2.3. BiobankPro: Software Description6.2.4. Recent Developments and Future Outlook6.3. Cryoport6.3.1. Company Overview6.3.2. Financial Information6.3.3. Cryoportal: Software Description6.3.4. Recent Developments and Future Outlook6.4. MasterControl6.4.1. Company Overview6.4.2. MasterControl Platform: Software Description6.4.3. Recent Developments and Future Outlook6.5. SAP6.5.1. Company Overview6.5.2. Financial Information6.5.3. SAP S/4HANA: Software Description6.5.4. Recent Development and Future Outlook6.6. Savsu Technologies6.6.1. Company Overview6.6.2. Financial Information6.6.3. evo Cold Chain 2.0: Software Description6.6.4. Recent Development and Future Outlook6.7. TraceLink6.7.1. Company Overview6.7.2. Financial Information6.7.3. Digital Supply Chain Platform: Software Description6.7.4. Recent Developments and Future Outlook

7. CELL ORCHESTRATION PLATFORMS: EMERGING TRENDS AND PROFILES OF KEY PLAYERS7.1. Chapter Overview7.2. Supply Chain Orchestration Platforms7.2.1. Key Functions of Supply Chain Orchestration Platforms7.2.2. Advantages of Supply Chain Orchestration Platforms7.2.3. Supply Chain Orchestration Platform Implementation Strategies7.3. Supply Chain Orchestration Platform: Trends on Twitter7.3.1. Scope and Methodology7.3.2. Historical Trends in Volume of Tweets7.3.3. Popular Keywords7.4. Key Industry Players7.4.1. Be The Match BioTherapies7.4.2. Clarkston Consulting7.4.3. Haemonetics7.4.4. Hypertrust Patient Data Care7.4.5. Lykan Bioscience7.4.6. MAK-SYSTEM7.4.7. sedApta Group7.4.8. Stafa Cellular Therapy7.4.9. Title 21 Health Solutions7.4.10. TrakCel7.4.11. Vineti

8. FUNDING AND INVESTMENT ANALYSIS8.1. Chapter Overview8.2. Types of Funding8.3. Cell and Advanced Therapies Supply Chain Management: Recent Funding Instances8.3.1. Analysis by Number of Funding Instances8.3.2. Analysis by Amount Invested8.3.3. Analysis by Type of Funding8.3.4. Analysis by Number of Funding Instances and Amount Invested across Different Software Solutions8.3.5. Most Active Players: Analysis by Amount Invested8.3.6. Most Active Investors: Analysis by Participation8.3.7. Geographical Analysis by Amount Invested8.4. Concluding Remarks

9. PARTNERSHIPS AND COLLABORATIONS9.1. Chapter Overview9.2. Partnership Models9.3. Cell and Advanced Therapies Supply Chain Management: Recent Collaborations and Partnerships9.3.1. Analysis by Year of Partnership9.3.2. Analysis by Type of Partnership9.3.3. Analysis by Partner's Focus Area9.3.4. Analysis by Type of Software Solution9.3.5. Most Active Players: Analysis by Number of Partnerships9.3.6. Analysis by Regions

10. PLATFORM UTILIZATION USE CASES10.1. Chapter Overview10.2. Cell and Advanced Therapies Supply Chain Management: Recent Platform Utilization Use Cases10.2.1. Analysis by Year of Utilization10.2.2. Analysis by User's Focus Area10.2.3. Analysis by Type of Software Solution10.2.4. Most Active Players: Analysis by Number of Utilization Instances10.2.5. Most Active Players: Regional Analysis by Number of Utilization Instances

11. VALUE CHAIN ANALYSIS11.1. Chapter Overview11.2. Cell and Advanced Therapies Value Chain11.2. Cell and Advanced Therapies Value Chain: Cost Distribution11.3.1. Donor Eligibility Assessment11.3.2. Sample Collection11.3.3. Manufacturing11.3.4. Logistics11.3.5. Patient Verification and Treatment Follow-up

12. STAKEHOLDER NEEDS ANALYSIS12.1. Chapter Overview12.2. Cell and Advanced Therapies Supply Chain Management: Needs of Different Stakeholders12.2.1. Comparison of Stakeholder Needs

13. COST SAVINGS ANALYSIS13.1. Chapter Overview13.2. Key Assumptions and Methodology13.3. Overall Cost Saving Potential of Supply Chain Management Software Solutions, 2019-203013.3.1. Cost Saving Potential in Donor Eligibility Assessment, 2019-203013.3.2. Cost Saving Potential in Sample Collection, 2019-203013.3.3. Cost Saving Potential in Manufacturing, 2019-203013.3.4. Cost Saving Potential in Logistics, 2019-203013.3.5. Cost Saving Potential in Patient Verification and Treatment Follow-up, 2019-2030

14. MARKET FORECAST14.1. Chapter Overview14.2. Key Assumptions and Forecast Methodology14.3. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market, 2019-203014.3.1. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application14.3.2. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by End User14.3.3. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Type of Software Solution14.3.4. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Mode of Deployment14.3.5. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Geography14.4. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application, Type of Software Solution and Mode of Deployment14.4.1. Cell and Advanced Therapies Supply Chain Management Solutions Market for Donor Eligibility Assessment, 2019-203014.4.2. Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection, 2019-203014.4.3. Cell and Advanced Therapies Supply Chain Management Solutions Market for Manufacturing, 2019-203014.4.4. Cell and Advanced Therapies Supply Chain Management Solutions Market for Logistics, 2019-203014.4.5. Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, 2019-2030

15. EXECUTIVE INSIGHTS15.1. Chapter Overview15.2. Thermo Fisher Scientific15.2.1. Company Snapshot15.2.2. Interview Transcript: Bryan Poltilove, Vice President and General Manager15.3. Cell and Gene Therapy Catapult15.3.1. Company Snapshot15.3.2. Interview Transcript: Jacqueline Barry, Chief Clinical Officer15.4. McKesson15.4.1. Company Snapshot15.4.2. Interview Transcript: Jill Maddux, Director, Cell and Gene Therapy Product Strategy, and Divya Iyer, Senior Director, Corporate Strategy and Business Development15.5. TrakCel15.5.1. Company Snapshot15.5.2. Interview Transcript: Martin Lamb, Chief Business Officer

16. CONCLUDING REMARKS16.1. Chapter Overview16.2. Key Takeaways

17. APPENDIX 1: LIST OF ADDITIONAL SUPPLY CHAIN MANAGEMENT SOFTWARE SOLUTIONS

18. APPENDIX 2: TABULATED DATA

19. APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS

For more information about this report visit https://www.researchandmarkets.com/r/kw1hkc

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Here is the original post:
Cell and Advanced Therapies Supply Chain Management Industry Report, 2019-2030 - GlobeNewswire

Prolotherapy is the use of a solution that helps grow stronger ligaments and tendons. Arthritis is considered a joint problem but the pain from arthritis is often caused by the surrounding soft tissue, which consists of these ligaments and tendons. Because of this, prolotherapy is a great treatment for a wide range of arthritic conditions. If you have arthritis, you have the opportunity to greatly benefit from prolotherapy.

Ligaments hold together bones. Around a joint they blend together to form a joint capsule. Tendons are said to connect muscles to bones, but it is more accurate to say that tendons are the continuation of the muscles that help connect the muscles to bones. This connection helps the muscles move the bones. The problem for both ligaments and tendons is that they do not get much blood flow. The difference in blood flow between the muscles and tendons and ligaments is highlighted by their color differences. Muscles are red with good blood flow, while ligaments and tendons are yellow-white, suggesting poor blood flow. So when they are injured, ligaments and tendons do not heal well. This contrasts with muscle which, when injured, tends to heal very well, often in four to six weeks.

Joint arthritis is thought of as the wearing out of bones that are connected. A common example is the knee joint. An x-ray of knee arthritis shows that the bones are closer together, called joint space narrowing (or on the spine, called disc space narrowing). Also seen on x-rays are bone spurs that grow off the bone. What is not well visualized on x-ray are ligaments and tendons. It is important to understand that loosening of ligaments plays a key role in the development of arthritis. Also, much of the arthritic pain is from the ligaments and tendons around the joint. By strengthening the ligaments and tendons with the prolotherapy solution, the arthritic pain can dramatically improve. Even when knee arthritis is severe, as in bone-on-bone, the pain can improve with prolotherapy. That is because much of the pain is coming from the ligaments and tendons, and even with severe arthritis the tendons and ligaments respond well to prolotherapy.

As a general rule, bone spurs result from loose ligaments. When a ligament is loose, the joint has intrinsic instability. Sometimes the instability is severe that the joint slips out of place. More often, there is mild laxity (looseness) such that the bones mildly rub against one another. In reaction to this physical stress, bone spurs develop as a way for the bone to protect itself. While the bone spur can cause some stiffness with movement, it usually does not cause pain. However, the unhealthy ligaments can cause significant pain. By improving the strength of the ligament, the joint pain will subside. When joint movement is affected by arthritis, the tendons also bear stress with the abnormal movement. These weakened tendons also produce pain. When the tendons are strengthened, the pain is significantly improved.

The shoulder is the most mobile joint in the body, so it is susceptible to arthritis. While they are considered different conditions, rotator cuff tendonitis and shoulder arthritis result from a similar cause. The rotator cuff is a group of four muscles that wrap around the shoulder like a cuff. By its name you can guess that the rotator cuff helps rotate the shoulder. Just as important, the cuff helps stabilize the shoulder, helps keep the shoulder joint in place when the arm is moving. When the ligaments weaken, this puts stress on the shoulder joint so bone spurs form and arthritis develops. At the same time, when the ligaments weaken, the rotator cuff muscles have to work harder. The cuff muscles then become strained, eventually progressing to a tear. Thus, rotator cuff injuries and arthritis form as part of this process. The good news is that because both problems involve ligament laxity and weak tendons, both conditions respond very well to prolotherapy.

Hips and knees are the key weight bearing joints so they are also vulnerable to arthritis. By strengthening the ligaments and tendons around knees and hips, the pain improves. Hands include our most used joints so they are also very susceptible to arthritis. Because they get so much use, the finger joints become stiff, painful and even deformed. While prolotherapy will not necessarily reverse the deformity, arthritic hand pain responds beautifully to prolotherapy. This is because the hand pain is caused by very small tender ligaments which are strengthened by prolotherapy.

While arthritis in the spine has different names including stenosis, spondylosis, facet syndrome and degenerative disc disease, they all have a similar underlying cause: lax ligaments. Even disc herniations are related to lax ligaments. Discs are sandwiched by the vertebrae (spine bones) and are made of fibrous tissue with a central gel-like substance. When the ligaments weaken, the vertebrae lose their support. This increases disc pressure, so the disc fibers weaken, eventually herniating or falling out. When the disc compresses the nerve, severe leg pain results, otherwise known as sciatica. As the discs wear out, the space between the vertebrae narrows, with bone spurs forming. This leads to the typical arthritic spine pain, known by the various names described above. This process is similar in the cervical spine (neck) and lumbar spine (low back). The key to understanding this is that it is lax ligaments which are a strong contributor to all these conditions. This is why prolotherapy is so effective for neck and back pain conditions.

Another key aspect of prolotherapy that complements its effectiveness is that it is very safe. As opposed to a steroid injection, which suppresses body functions and has to be limited due its toxicity, prolotherapy stimulates the bodys healing reactions so it can be repeated, if necessary, and can be used for multiple areas of pain. As opposed to arthroscopy, which treats arthritic pain by cutting away loose tissue fragments and bone spurs, prolotherapy treats arthritic pain by building and strengthening tissue for long-term healing.

In summary, prolotherapy is a great treatment for arthritis affecting multiple joints, including the most commonly affected joints such as the shoulders, hips, knees and fingers, and even less commonly affected joints such as the elbows, wrists, ankles and toes, and also anywhere along the spine including the neck and low back. The reason it is so effective for arthritis is because the pain caused by arthritis is often caused by lax ligaments and these ligaments are strengthened by prolotherapy. Please check my website where I describe the logistics of prolotherapy (Prolotherapy Info) and go into more detail about how prolotherapy works (How Prolotherapy Works).

Dr. Slaten is a pain wellness physician in Ridgewood. For more than 20 years, he has been practicing with great skill and an open mind. Learn more about prolotherapy and his other treatments at his website, http://www.njprolo.com.

More:
Prolotherapy Is a Great Treatment for Arthritis - Jewish Link of New Jersey

While most polar bears live only to their mid-20s, Boris recently celebrated his 34th birthday, meaning hes probably the oldest male polar bear on the planet, and hes living out his best retirement years at Point Defiance Zoo & Aquarium after living treacherously with a traveling circus.

At 11:01 a.m. on an unseasonably warm morning, Point Defiance Zoo & Aquarium staff biologist Cindy Roberts exited the backstage area of the zoos polar bear exhibit and arrived moments later in the public viewing area for her two furry, white charges.

My name is Cindy, Im a staff biologist, and Im lucky enough to work with our two polar bears, Roberts said with an energetic smile as she addressed the families that had accumulated in front of the exhibit.

We have Blizzard, who is our younger bear; he is going to be 24 years old, Roberts continued. And we also have Boris, who is our really old bear; he (turned) 34 on Dec. 15th.

Blizzard was standing just beyond the exhibits saltwater pool. Elsewhere, hidden from the view of the crowd, Boris lounged indoors with his hind legs spread straight out behind him as he laid on the floor and pawed languidly at an ice treat fillets of salmon in a block of ice in front of him.

The 873-pound-bear is perfectly content, and despite some common elderly issues skin and liver problems, arthritis, and bad teeth from years of mistreatment hes living a happy, healthy life.

Prior to coming to Point Defiance in the early aughts, Boris lived a storied life with two circus productions. He was born in a German zoo in the mid-1980s, and at 18 months old, started performing with Ursula Bttcher, one of the most celebrated female animal trainers in the world, who was particularly famous for performances with polar bears.

She took care of those bears very well for that time period, Roberts said of the research shed done on Bttcher and her act. If she thought anyone was harming them in any way, she would fire them instantly.

However, after the fall of the Berlin Wall and the unification of Germany in 1989, the state-run East German circus that effectively owned Boris began to be phased out, and by the late 1990s, the bears had been sold. Some remained in Europe, but most were sold to the Suarez Brothers Circus in Mexico.

The Suarez Brothers badly mistreated the bears, feeding them a feeble diet of bread and lettuce and housing them in small cages without room to swim or cool off. The bears were eventually seized by American authorities after the zoo traveled to Puerto Rico a U.S. territory.

A YouTube video taken around the time of the bears seizure shows the massive mammals crammed into small cages atop a trailer. The bears were panting, drooling, and swaying side to side in an attempt to cool themselves.

Our vet at the time, Dr. Holly Reed she has since passed away she actually transported the bears to the U.S., and they were in pretty bad shape, Roberts said. We got Boris and Kenny the other bears went to Baltimore, Detroit, and North Carolina.

Though Roberts was not at the zoo when Boris arrived, she has now worked with him for more than a decade, and he holds a special place in her heart.

Hes just an amazing animal because of his history, she said. I think not only does (his story) give us all passion for polar bears in general, but it gives us hope in facing challenges and getting to the other side where you get salmon treats and you dont have to go outside.

Born: Dec. 15, 1985

Weight: 873 pounds

Height: 5 feet

Diet: Raw ground meat, fish, beef fat, and specially formulated kibble

Pounds of food per day: 7.5 to 21

Medication: 134 pills a day

Fun fact: He was the first polar bear to receive a stem cell transplant, to help lessen the effects of his arthritis.

Save the date

Interested in learning about how to help polar bears like Boris live long, healthy lives? Consider attending the zoos annual Party for Polar Bears, presented by the Point Defiance Chapter of the American Association of Zookeepers from 5 to 9 p.m. on Feb. 24, at Dystopian State Brewing in Tacoma. More information here.

Originally posted here:
The Oldest Polar Bear in the World Likely Lives in Tacoma - 425magazine.com

The report titled Global Psoriatic Arthritis Treatment Market Size, Status and Forecast 2019-2025 provide (6 Year Forecast 2019-2025)enhanced on worldwide competition by topmost prime companies (Eli Lilly, Roche, Merck, Novartis, Abbvie, Amgen, Bristol Myers Squibb, Celgene Corporation, Janssen, Valeant Pharmaceuticals) which providing information such asCompany Profiles, Capacity, Gross, Gross Margin, Product Picture and Specification, Production, Price, Cost, Revenueand contact information. This Psoriatic Arthritis Treatment market report crucial insights that facilitate theMarket Trends, Drivers, Market Dynamics, Overview, Scope, Definitions, Classifications, Opportunities, Competitive Landscape. The report provides key statistics on the market status of the Psoriatic Arthritis Treatment market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

Get Free Sample PDF (including full TOC, Tables and Figures)of Psoriatic Arthritis Treatment [emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2237281

Target Audience of Psoriatic Arthritis Treatment Market :Key Consulting Companies & Advisors, Production Companies, Suppliers,Channel Partners, Marketing Authorities, Subject Matter Experts,Research Institutions, Financial Institutions,Market Consultants, Equipment Suppliers/ Buyers, Industry Investors/Investment Bankers Government Authorities.

Scope of Psoriatic Arthritis Treatment Market:The report affords a basic outline of the Psoriatic Arthritis Treatment Market report contains definitions, competitive landscape evaluation, segmentations, applications, key providers, market drivers and challenges. The Psoriatic Arthritis Treatment Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data.

On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-

Kits Reagents Instruments

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Psoriatic Arthritis Treatment market for each application, including-

Hospitals Clinics Ambulatory Surgery Centers Diagnostic Laboratories

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2237281

Psoriatic Arthritis Treatment Market: Regional Analysis Includes:

The Psoriatic Arthritis Treatment Market Report Can Answer The Following Questions:

What is the (North America, South America, Europe, Africa, Middle East, Asia, China, Japan) production, production value, consumption, consumption value, import and export of Psoriatic Arthritis Treatment market?

Who are the key manufacturers of Psoriatic Arthritis Treatment market? How are their operating situation (capacity, production, price, cost, gross and revenue)?

What are the upstream raw materials and manufacturing equipment of Psoriatic Arthritis Treatment? What is the manufacturing process of Psoriatic Arthritis Treatment?

Economic impact on Psoriatic Arthritis Treatment industry and development trend of Psoriatic Arthritis Treatment industry.

What will the Psoriatic Arthritis Treatment market size and the growth rate be in 2025?

What are the key market trends impacting the growth of the Psoriatic Arthritis Treatment market?

What are the Psoriatic Arthritis Treatment market challenges to market growth?

What are the Psoriatic Arthritis Treatment market opportunities and threats faced by the vendors in the Psoriatic Arthritis Treatment market? Etc.

Contact:

ResearchMozMr. Nachiket Ghumare,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]

Browse More Reports Visit @https://bit.ly/2Sepby2

This post was originally published on Market Research Sheets

See the rest here:
Psoriatic Arthritis Treatment Market Advance Technology And New Innovations 2020 To 2025 -Eli Lilly, Roche, Merck, Novartis - Market Research Sheets

This article was originally published here

Development and validation of a clinical rule for recognition of early inflammatory arthritis.

BMJ Open. 2019 02 22;8(11):e023552

Authors: Ten Brinck RM, van Dijk BT, van Steenbergen HW, le Cessie S, Numans ME, Hider SL, Mallen C, van der Helm-van Mil A

AbstractOBJECTIVES: National and international guidelines recommend prompt referral of patients presenting with inflammatory arthritis (IA), but general practitioners (GPs) feel uncertain in their proficiency to detect synovitis through joint examination, the method of choice to identify IA. Our objective was to develop and validate a rule composed of clinical characteristics to assist GPs and other physicians in identifying IA when in doubt.DESIGN: Split-sample derivation and validation study.SETTING: The Leiden Early Arthritis Recognition Clinic (EARC), a screening clinic for patients in whom GPs suspected but were unsure of the presence of IA.PARTICIPANTS: 1288 consecutive patients visiting the EARC.PRIMARY AND SECONDARY OUTCOME MEASURES: Associations of clinical characteristics with presence of IA were determined using logistic regression in 644 patients, while validating the results in the other 644 patients (split-sample validation). To facilitate application in clinical practice, a simplified rule (with scores ranging from 0 to 7.5) was derived and validated.RESULTS: IA was identified by a rheumatologist in 41% of patients. In univariable analysis, male gender, age 60 years, symptom duration <6 weeks, morning stiffness >60min, a low number of painful joints (1-3 joints), presence of patient-reported joint swelling and difficulty with making a fist were associated with IA in the derivation data set. Using multivariable analysis, a simplified rule consisting of these seven items was derived and validated, yielding an area under the receiver operator characteristic curve (AUC) of 0.74 (95% CI 0.70 to 0.78) in the derivation data set. Validation yielded an AUC of 0.71 (95% CI 0.67 to 0.75). Finally, the model was repeated to study predicted probabilities with a lower prevalence of inflammatory arthritis to simulate performance in primary care settings.CONCLUSIONS: Our rule, composed of clinical parameters, had reasonable discriminative ability for IA and could assist physicians in decision-making in patients with suspected IA, increasing appropriateness of healthcare utilisation.

PMID: 30798292 [PubMed indexed for MEDLINE]

Go here to read the rest:
Development and validation of a clinical rule for recognition of early inflammatory arthritis. - DocWire News

Few people know that the seasonal SARS hides more dangers than it seems. Incorrect or incomplete treatment of the common cold can affect the human body severe pain with every movement because of the infection of the joints.

Getting arthritis or gout possible due to seasonal and SARS, which often suffer from fall and winter. The common cold will develop into pain and deformity of the joints, if you just ignore it or MIS treated. Its all in the bloodstream, which carries the infection throughout the body from the affected areas. Weakened by the struggle with a cold, the immune system literally can miss the infection of the joints, especially if the person recently stood in the cold or got hypothermia.

To lose joints possible not only after you sneeze or cough, but promiscuous sex and urinary tract infection. The infection acts on the same principle that SARS travels through the bloodstream and infects cartilage, bringing the man down. Such rogue infection develops reactive arthritis, a dangerous disease that is very difficult to diagnose.

Under threat and people in the reverse situation, when the immune system is working at 120% because of the medicine. He can be overzealous after the suppression of the disease, and begin to attack the cartilage of joints, causing rheumatoid arthritis. The disease quickly immobilizes a joint and switched on the nearby tissue, which is extremely dangerous.

The main danger of such a receiving arthritis in that it is extremely difficult to diagnose and successfully cure it is possible only at the initial stage (both diseases). Because doctors do not advise to delay going to the hospital, or instead of therapy and pills, the patient will have to lie on the operating table and undergo a long rehabilitation.

Maria Batterburyis a general assignment reporter at the Saxon. She has covered sports, entertainment and many other beats in her journalism career, and has lived in Manhattan for more than 8 years. Vivian has appeared periodically on national television shows and has been published in (among others) NPR, Politico, The Atlantic, Harpers, Wired.com, Vice and Salon.com..

Link:
SARS can cause arthritis and gout - The Saxon

Glaucoma is the leading cause of irreversible blindness in the world and the United States.

The number of people with glaucoma worldwide is estimated to be over 70 million and is expected to increase to over 110 million by 2040. It currently affects more than 3 million people in the United States and is the leading cause of blindness in both African American and Hispanic populations. This is despite the fact of a low overall prevalence of 3.5 percent.

Glaucoma belongs to a class of eye diseases known as optic neuropathy. There are two main types of glaucoma: open angle and narrow or closed angle. The angle is the opening where the fluid drains from the eye. In narrow angle, the channel is blocked and the fluid cant exit. With open angle, the channel is not obstructed. In the western world, 90 percent of glaucoma is of the open angle type.

Vision loss is caused by progressive damage to the optic nerve. The eye is similar to a video camera. It is connected to the vision center in the brain by a cable that is called the optic nerve. The nerve is a bundle of about 1 to 1.5 million nerve fibers. In glaucoma, for a reason we still do not fully understand, these fibers begin to die off. Without proper treatment, the number of fibers will continue decline and, with that, the patients vision.

It used to be thought that the loss of nerve fibers was the result of a high pressure inside the eye. Studies have shown that damage can actually occur at normal or even low pressures. Current thinking is that an elevated pressure is a risk factor for glaucoma but not the disease itself. As it is the only risk factor that can be treated, all current treatment of glaucoma involves lowering the eye pressure. This can be achieved by using topical medication (drops), laser therapy, surgery or a combination of treatments. Successful treatment will lower the pressure to the point that no further nerve fibers and, hence, vision will be lost.

There are three main reasons why people go blind from this disease. First, they are not diagnosed. Recent studies have estimated about 1 million people in the United States with glaucoma are currently undiagnosed. Although many factors are involved here, the two main culprits are lack of symptoms until very late in the disease and failure to routinely have a thorough eye examination.

The second reason is that patients are notoriously non-compliant with their therapy. There have been many papers, articles and even YouTube videos about this. But the bottom line is thisno treatment is effective if it is not used.

Finally, treatment has to be sufficient to slow or stop disease progression. If therapy is inadequate, the benefit of accurate diagnosis and compliance will suffer.

Glaucoma can be diagnosed at any age, but is more common after the age of 40. Vision loss is completely preventable with early diagnosis and proper treatment. This cannot happen without routine eye examinations. A minimum examination would consist of a measurement of eye pressure and a dilated stereoscopic evaluation of the optic nerve. If there is evidence of increased risk, a more detailed investigation would include formal test of the visual field and optic nerve imaging.

Rememberglaucoma is known as the silent thief of sight as there are no symptoms until late in the disease. If you are over 40, have a family history of glaucoma or any other risk factors, make sure to have your eyes examined regularly.

Dr. John J. ODonnell Jr. is an optometrist with Premier Eye Care Group. For more information, visitwww.premiereyes.com.

The rest is here:
The Silent Thief: Glaucoma can steal your sight, but vision loss is preventable. - The Burg News

Lets face it. Doesnt the year 2020 make you think of 20/20, supposedly the description of ideal vision? Were entering a year that sounds more like something youd hear during a visit to the optometrist than the vision of whole new worlds of opportunities just over the next hill.

The fact that I can see a written 2020 at all is probably thanks to my first-grade teacher, Fern Bairey. I assume she was the one who noticed that I couldnt see the blackboard in her classroom. I got my first set of eyeglasses shortly after entering her classroom in Reliance. Until then, I didnt know a kid was supposed to see the shapes of tree leaves and the tassels on the ears of corn in the fields.

I had a cowlick and a round face, so when I got my eyeglasses, I looked like Ralphie, the kid in A Christmas Story. Classmates made fun of me, naturally. It was only years later that I saw a billboard with a glasses-wearing kid who looked like first-grade me. The slogan said, Dont laugh. Now he can see. I wish Id seen that back in Reliance.

Ive worn glasses since Miss Baireys class. My optometrists told me years ago my vision was, lousy and likely to get worse. It did. Last time I checked, my vision was about 20/200 in one eye and 20/400 in the other. I got my first pair of contact lenses when I entered college, and Ive worn those ever since, although I generally switched back to glasses when I had to work around wheat chaff or corral dust during college summers on the farm.

One of my craziest experiences with contact lenses came at the end of my senior year in college when I was considering a career in the U.S. Air Force. Along with a whole bunch of other young men who had been told they could write their own ticket if they enlisted for a four-year-hitch, I went through the physical exam process in Sioux Falls, at the Post Office building, I think it was. The impatient Air Force guy hustled us through the line so quickly that when he barked at me to put your eyes to the scope and read the letters, I did it without mentioning my contact lenses. Imagine my surprise when they rated me 20/30 and good to go for training as a navigator.

As is often the case, the loud, impatient guy whose yelling helped create the problem wasnt the one who had to listen as I explained that my vision really was 20/400, that it probably hadnt been anywhere close to 20/30 even when I left the Mitchell hospital in January of 1944 and that the mix-up, if truth be told, happened because the mean guy didnt give me a chance to tell him about my contacts.

The episode kind of soured me on a career in the Air Force writing news releases for home-town newspapers about the activities of their service members. (The first time I talked with the on-campus Air Force recruiter in the spring of 1966, he asked me my major. When I said journalism, he told me there was more than a good chance that if I enlisted after graduation, Id spent my military career at a base somewhere in Texas writing those home-town news blurbs. That didnt sound so bad to me, although Texas?) After the contact lens incident, I never got the impression that the Air Force was sorry to see me miss out on the chance to don a uniform with the blue from the skies and a pretty girls eyes and a touch of Old Glorys hue, as the song goes.

In the interests of full disclosure: The Air Force sent me to a psychiatrist because, when asked, I said I sometimes had difficulty sleeping. Theyd probably have been money ahead if theyd sent me to an optometrist.

Read more:
Woster: 2020, good eyesight or a new year? - The Daily Republic

Eyesight Technologies, a leading provider of computer vision AI solutions for the in-car automotive industry, and Grupo Antolin, one of the largest manufacturers of vehicle interiors in the world, announced today that the companies have entered into a partnership to provide driver and occupancy monitoring solutions to OEMs worldwide.

Grupo Antolins ability to integrate 3rd party solutions into its car interior components and the development of their control electronics will be paired with Eyesight Technologies advanced in-cabin sensing solutions (Driver Sense and Cabin Sense) to deliver smart-integrated interior systems with great added value.

The collaboration will provide car manufacturers with in-cabin sensing solutions tailored to answer regulatory needs and enhance the driving & riding experience, leveraging Eyesight Technologies computer vision AI and Grupo Antolins interior component design and integration capabilities.

Eyesight Technologies solutions encompass a variety of applications related to driver and passenger safety and experience inside the vehicle. Eyesight Technologies Driver Sense, driver monitoring system, tracks the drivers eyes, eyelids, pupils, head pose, and gaze to determine the alertness, wakefulness, and attentiveness of the driver. The companys Cabin Sense, occupancy monitoring system, monitors the cars interior, including passengers, to power adaptive safety features, and a personalized in-car environment. Driver identification and action detection such as smoking, wearing seatbelt and holding a phone are also available as part of Eyesight Technologies solutions.

SOURCE: Eyesight Technologies

Read more:
Grupo Antolin and Eyesight Technologies team up to provide intelligent in-cabin monitoring solutions - Automotive World

And so begins a new year. It rolls by on a fairly annual basis, but each time, I feel quite unprepared to make the switch. Awkwardly, the other day I wrote 2016 on something; I guess if Im going to be behind the times, I might as well go for it.

Im thinking, though, that 2020 has a nice enough ring that Ill get the hang of it quicker. Well see what happens.

Chinese culture attributes a certain animal to each calendar year, rotating through a set of 12 options ranging from rabbits to tigers. 2020 would be the Year of the Rat, but I had enough experience with rats in Kenya and Im not really into them.

Since vegetables are more down my alley, Ive decided to make an executive decision and deem 2020 the Year of the Carrot!

It makes perfect sense to me 20/20 means you have pretty good vision, and what vegetable is classically associated with good vision? Carrots, of course.

My logic starts to break down immediately when I explain that much of that belief is based on urban myth. The well-perpetuated notion that carrots can help you see in the dark, and drastically improve your eyesight in general, is actually due to World War II propaganda. In order to disguise new radar technology, the British army praised carrots as their secret weapon in obtaining night vision.

I guess their ploy worked because weve been believing it ever since.

To be fair, carrots definitely arent bad for your eyes. They are such great sources of vitamin As precursor, beta carotene that, yes, it is named after them. Vitamin A can at least help maintain good vision, and severe deficiency can contribute to loss of eyesight.

But carrots arent the winning sources of vitamin A: liver products can have up to over ten times the amount of carrots. Sweet potatoes, winter squash, and even hearty greens can all be denser vegetable sources than carrots.

On a similar note, although we typically refer to 20/20 as perfect vision, it isnt. It denotes normal visual acuity, but 20/15 or even 20/10 would be much better, as it means you can see with clarity things 20 feet away that 20/20 people can only see closer at 10 feet away.

All that said, I still choose carrots because I love them so much. Besides, I dont plan on advocating a Year of Liver any time soon.

And I still think vision is good to consider at the beginning of this new year. In the coming months, what will you be looking for? Are your eyes open to daily blessings? Are you really seeing the people around you?

So go ahead and make black-eyed peas or cornbread for New Years if you want; go ahead and make New Years resolutions if you want. But just make sure you make carrots, too.

Amanda Miller writes a column about local foods for The Hutchinson News. She teaches classes at Apron Strings and makes cheese on her familys dairy farm near Pleasantview. Reach her at hyperpeanutbutter@gmail.com

See the article here:
2020 vision for all of us - The Hutchinson News

Rhonda Abrams, Special to USA TODAY Published 8:00 a.m. ET Jan. 1, 2020

Happy New Year and welcome to the year of20/20 Vision for Success in your small business.When someone has 20/20 vision, it means they have excellent eyesight.Solets make 2020 the year you can clearly see success ahead.

Youll need:

One of Rhondas Rules is You cant reach a goal you havent set. In other words, you have to identifythe goals you want to reach in the next 12 months. What do you want your business to become? What is your definition of success?I rarely quote the Bible in my column, but I would remind you of Proverbs 29:18 Where there is no vision, the people perish.

The same is true in business. When you dont have a clear and sensible vision for what you want to achieve, then your business will perish.

(Photo: GETTY IMAGES)

20/20 Vision: I want you to have a really defined vision for your small business in 2020. This is more than just a vague sense of what youd love to achieve (I want to be famous. I want to be the most successful realtor on the West Side. I want to have a really successful app.). But for 20/20 vision, you need to both name and quantify your goal. (I want to launch my water use tracking app by June and get 900 users by the end of the year.)

You cant just setgoals,you need a roadmap on how to best reach those goals. Whattasks must you accomplish to reach those goals?Whatresourceswillyou needmoney, personnel?What steps are crucial? What activities should you put aside until next year?

More: Small-business owners need policies, strategy to keep the workplace safe

More: Start 2020 off right: Take 6 smart small-business steps before the end of the year

More: Looking for a small-business role model? Check out these celebrity entrepreneurs

20/20 Vision:You need a business plan.Sosit down in early January and begin working on it create both a long-term business plan and an annual plan.I believe in this so much that I wrote the book on it:Successful Business Plan: Secrets & Strategies.

If you want something to thrive, you have to focus your attention on it. One of the most difficult challenges for small business owners is they must take care of so many competing tasks that its difficult to stay focused. In 2020, be sure toidentify the tasks that aretruly most importantto achieveyour definition of success. Make sure youfocus on thoseeven as you have to tend to day-to-day tasks.

20/20 Vision:Find yourself a good organizing tool one that works for you. It may be a software program like Trello(I just used that to manage my entire kitchen remodel) or Monday. Oryou may like to see your priorities and tasks written out on paper. My friend swears by Bullet Journaland I use a simple spiral bound notebook that is always with me.

Your business doesnt operate in a vacuum. You need to see whats going on in your industry, with your competition, with your target market.

20/20 Vision:Join an industry trade group. Subscribe to industry newsletters, listen to industry podcasts. Visit your competitors websites regularly. And read trustworthy news outlets that rely on facts.

You need to make sure you pay attention to the details of your business, not just the big picture. In particular, keep a close eye on your financial situation. Find ways and choose tools that keep your eye on your financial resources and your bottom line.

20/20 Vision:Automate as many payments as you can so theyre always made on time. Download mobile apps you have available from your accounting software programs, banks, credit cards, so you can easily and regularly check on your finances. Monitor how you send out invoices, deposit payments, pay bills so you make sure your internal processes are both safe and streamlined.

Together lets see howwe can make 2020 the best year ever.

Rhonda Abrams is the author of "Successful BusinessPlan: Secrets& Strategies," the best-selling business plan guide in the US, just released in its seventh edition.Connect with Rhonda on Facebook, and Twitter and Instagram: @RhondaAbrams. Register for Rhondas free business tips newsletter at http://www.PlanningShop.com.

Read or Share this story: https://www.usatoday.com/story/money/usaandmain/2020/01/01/small-business-success-plan-2020/2784462001/

View post:
20/20 vision in 2020: Name and claim small business success - USA TODAY

George Randall Jr.

It seems like just yesterday the calendar flipped over to the year 2000, and many were concerned about the Y2K problem; wondering if all our computers, and everything linked to them would crash. I remember certain radio (false) prophets telling everyone to go stockpile food for the end of civilization, as we know it. All that worrying for nothing.

Now here we are at the New Year 2020. God is still Almighty, and everything is still under His authority and power. He is still good and faithful to provide, protect, and give His peace to each one who trusts in Him, each day we continue here on Planet Earth. We can still trust Him with our lives.

Please receive and meditate on each Scripture. Matthew 6:25-34, Therefore I say unto you, Take no thought for your life, what ye shall eat, or what ye shall drink; nor yet for your body, what ye shall put on. Is not the life more than food, and the body than raiment? Behold (look at intently, take notice, observe and consider carefully) the birds of the air: for they sow not, neither do they reap, nor gather (their crops) into barns; yet your Heavenly Father feeds them. Are ye not much better than they? If God so clothe the grass of the fieldshall He not much more clothe you, O ye of little faith? Therefore (because of this great assuring truth) take no thought, saying, what shall we eat or, what shall we drink? But seek ye first the Kingdom of God, and His righteousness; and all these things shall be added unto you.

Do you have 2020 vision? One of my three darling daughters works in an eye doctors office where I am also a patient. Ive been told that perfect vision for a human being is 20/20. We are now in the year 2020, and I wonder what we might see this year. I hope my friend, that our eyes will be open to the Word of God, and to the work of God. I hope we will have a clear vision for lost souls who need Jesus in this broken world. I hope we see the talents God has given us to lovingly invest in people for His Kingdom.

Is your heart available for Gods Spirit to move through, to accomplish His will and purpose? Will you lift up Jesus in witness and worship so all people will see Him, and many believe on Him? Are your spiritual eyes open? Proverbs 29:18 states, Where there is no vision, the people perish. Souls are perishing; some are dying without any clear sight of the Savior. Perhaps they would see the Savior, Jesus Christ if we would proclaim Him more boldly, and display Him more faithfully in our lives, fellow Christian. (John 4:35, lift up your eyes and look) Perhaps the lost would look deeper into the satisfying of their spiritual need if we would kindly share with them our relationship with our LORD. Is our relationship with the LORD where it should be? If not, each day is a new day. Start over!

Exodus 20:20, And Moses said unto the people, Fear not: for God is come to prove you, and that His fear may be before your faces, that ye sin not.

First notice the location of this verse; its 20:20. I believe thats no coincidence. Even though there were no verses marked in the original Hebrew, consider Gods divine inspiration over the complete translation of His Word into the English Language, circa 1535-1560. Consider the position of this verse, and its powerful content. I believe there is a great revelation here for us to see with eyes wide open and attentive. Its about clear 20/20 vision.

Is His fear before your face, before your eyes? Do we fear God to the point of turning away from sin and its dire consequences? Do we love Him enough to embrace His righteousness, to be His children of light? I believe this will be a year for God to prove us. Websters 1828 Dictionary defines prove as, to try; to examine; to ascertain some unknown quality by an experiment, test or standard.

When we are put to the test, will we wholeheartedly rely on our Heavenly Father by faith? Will we come forth refined as silver and gold? Will we ask our Father to fill us with His Holy Spirit, to guide and rule our lives? Will we choose His Kingdom over serving self, and the vain things of this corrupt world? May our answer be yes Lord.

We are at another point of decision, at another opportunity to take the high road. Let us accept Gods mission to be agents of compassion toward desperate, but precious souls, and, may we be ambassadors of the Gospel message. In Gods Word is supernatural life changing spiritual power over darkness. Have 20/20 vision my friend. My prayer; Dear Father, In this new year of 2020, may Your Kingdom come, Your will be done in Earth, and in us as it is in Heaven; because, Yours is the kingdom and the power and the glory for ever and ever. Amen.

George Randall Jr.

George Randall Jr. is the minister to youth at Rocky Ford Christian Church in Cana, Virginia.

Go here to see the original:
Do you have 2020 vision? - Mount Airy News

By: Lifestyle Desk | New Delhi | Published: January 2, 2020 3:20:27 pm Unhealthy food, old age eyesight, red meat, fried foods, high-fat dairy. (Source: Getty/Thinkstock Images)

Keep an eye on what you eat, as a recent study has found a link between an unhealthy diet and vision loss at an older age. After researching for around two decades, results have shown that a diet rich in red meat, fried foods, high-fat dairy, processed meats and refined grains can badly impact eyesight. The study, published in the British Journal of Ophthalmology, says there are links between a diet rich in unhealthy foods and age-related macular degeneration.

The condition that impacts the retina with age, blurs central vision that is required to see objects clearly and perform everyday activities such as reading and driving. According to the Centers for Disease Control and Prevention (CDC), in the United States, around 1.8 million people aged 40 and above are living with AMD, and another 7.3 million have a condition called drusen, which usually precedes AMD.

Senior study author Dr Amy Millen, of the University at Buffalo in New York, told Medical News Today, Most people understand that diet influences cardiovascular disease risk and obesity; however, Im not sure the public thinks about whether or not diet influences ones risk of vision loss later in life. We wanted to examine how the overall pattern of ones diet may predict later development of AMD, both early-onset and late-stage disease. What we observed in this study was that people who had no AMD or early AMD at the start of our study, and reported frequently consuming unhealthful foods, were more likely to develop vision-threatening, late-stage disease approximately 18 years later.

The study looked at 66 different food types, which they later categorised into prudent, which included healthy food and western, which includes processed, red meat, fried stuff, etc. Although the researchers found no link between early AMD and dietary patterns, they found that the incidence of late AMD was three times higher among those with a Western diet pattern.

For all the latest Lifestyle News, download Indian Express App

IE Online Media Services Pvt Ltd

Read the original:
Unhealthy food could badly impact eyesight: Study - The Indian Express

Jeff Gill, Guest Columnist Published 4:00 p.m. ET Jan. 3, 2020

How many ways have we seen 2020 as a year conflated with 20/20 as a measure of vision?

I was in seminary when I first heard reference to goals and planning towards the year now begun, mixing up the usual metric for clear vision with the Anno Domini, Year of Our Lord Two thousand and twenty.

And I hate to tell you, but it was 35 years ago.

Thats almost four decades of beating that metaphor into the ground, and its with a measure of relief I mark not just having lived to this date, but seeing it start to move past us. No more 20/20 riffs or reminders or relationships.

Im not a person with 20/20 vision. Ive worn glasses since third grade and probably needed them earlier than that. Im about 20/60 in one eye and 20/200 in the other.

What that means in everyday terms is that what the normal person can see at 200 feet of, say, a set of letters on a poster, I can only see at 20 feet. 20/20 vision just means that you see at 20 feet of distance what most people see from 20 feet away. Thats why a person with truly acute vision might have 20/15 vision, because they can see at 20 foot range what the basically enabled watcher would need to step five feet closer to make out.

Which is where I think the idea of labeling a visioning process for a church or any other faith community as 20/20 vision is not a sign of acuity or excellence, but youre actually asking for the average, the generally accepted. And is that the kind of vision we want in our spiritual insight?

Id hope, as a congregation, that my church members would ask and pray and work for a measure of vision that is better than the run-of-the-mill eyesight. Certainly, we dont want worse, and Im glad to have my own corrective lenses to get me roughly back up to 20/20, but our hopes for vision and anticipation should be more for . . . well, how do they measure telescopes or microscopes?

So, to see well into the future, we might want to aspire to 28x vision like a good home telescope, or for insight 100x magnification akin to a desktop microscope. Thats the kind of vision worth pursuing, dont you think?

Anyhow, 20/20 is dead-on average, and while thats useful and common, I think the year 2020 is a good time to retire that image, and maybe even rethink the whole concept of vision statements. Mission statements have been boiled down to a phrase or short set of words for quite a while now; you dont see long mission statements as a standard quote line on either business or non-profit documents very often anymore. Its not to be the leader in every market we serve, to the benefit of our customers and our shareholders or a company that builds value for its shareholders through its employees by creating an atmosphere of optimism, teamwork, creativity, resourcefulness and by dealing with everyone in an open and ethical manner. Now, youre more likely to see Peace of mind or To inspire humanity.

A vision statement should state the goal youre working together to achieve, and a mission statement your particular part of making progress towards that vision. My own congregation filed a very forward looking vision statement with the Ohio secretary of state back in 1891: To glorify God and better humanity. While we have a more recent and much longer mission statement, we work with a simplified condensation of it as Worship, Serve, Grow. Those three words offer a visitor or guest our sense of how our church is participating in that larger vision to glorify God and better humanity through the values of corporate worship, shared service, and a commitment to personal growth in spiritual maturity.

How does your church community envision the goal youre together to support? And what are you particularly called and gifted to accomplish in that pursuit as a local church? Im betting you can do better than an average, common, 20/20 vision of those ends.

Jeff Gill is a writer, storyteller, and pastor in Licking County; tell him how youre thinking about vision atknapsack77@gmail.com, or follow @Knapsack on Twitter.

Read or Share this story: https://www.newarkadvocate.com/story/opinion/2020/01/03/faith-works-you-might-surprised-what-you-see/2794032001/

Original post:
Faith Works: You might be surprised by what you see - The Newark Advocate